An open-label randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer patients following prior anthracycline and taxane therapy
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Indisulam (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 06 Mar 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 27 Oct 2005 New trial record.